Financial Trade Freedom - Investing and Stock News
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
No Result
View All Result
Financial Trade Freedom - Investing and Stock News
No Result
View All Result
Home News

Republican senators blast FDA for expanding abortion pill access

admin by admin
October 30, 2025
in News
0
Republican senators blast FDA for expanding abortion pill access
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Republican senators on Wednesday urged the Food and Drug Administration (FDA) to tighten safety standards and reconsider partnerships tied to abortion pills, accusing the agency of expanding access without adequate oversight.

On the call, Sen. Josh Hawley, R-Mo, and Sen. Bill Cassidy, R-La., expressed frustration that the agency hadn’t already overhauled safety parameters around abortion pills — and that it had instead expanded its partnerships with producers of the drugs that make chemical abortions available.

‘My plea to the FDA is to follow the science to put back safety guardrails,’ Hawley said. ‘I’ve called on the director of the FDA to take these steps. The public deserves to have answers.’

The press conference held by the senators indicates that abortion policy is still a mainstay priority for some Republican lawmakers — even as President Donald Trump has previously signaled contentment with leaving questions about abortion policy at the state level. Hawley and Cassidy both questioned the safety of chemical abortions and their proliferation.

Notably, Republicans passed a short-term prohibition of Medicaid funding from going to nonprofit organizations that provide abortions as part of its One, Big Beautiful Bill Act that became law earlier this year.

But that change hasn’t stopped Hawley and other lawmakers from torching the FDA for announcing a partnership with Evita Solutions, looking to create a new version of the key abortion drug, mifepristone.

‘When I heard the FDA approved another generic form of misoprostol, I was upset,’ Sen. Cassidy said, referring to the drug often used in conjunction with mifepristone. ‘I call them up, ‘Why are you doing this?’’ 

Cassidy joined 17 other Republican senators in sending a letter to the FDA earlier this month, demanding to know why the agency had approved a new form of the abortion drug. They asked for an answer by Oct. 30.

Cassidy said the group has not received anything from the agency.

‘They have not responded, but the government’s been shut down, and so I’m sure they would say, ‘Well, we can’t respond,’ but we will have the FDA commissioner to come in and speak to FDA issues.’ 

Without mifepristone and misoprostol, most of the country’s abortions would be impossible. 

The pair of compounds undermine the vitality of a pregnancy and prompt the body to expel pregnancy tissue. According to the Guttmacher Institute, a sexual health and reproductive rights organization, mifepristone was used to induce 63% of all U.S. abortions in 2023. 

‘This is shocking,’ Hawley said in a post to X earlier this month. ‘FDA just approved ANOTHER chemical abortion drug, when evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course, 100% lethal to the child.’

Hawley claimed on Wednesday that 11% of women who use a chemical abortion experience some sort of adverse health event.

‘The science is really quite significant. We’ve just had one of the largest studies ever performed of claims relating to chemical abortions based on insurance data. It came out this summer — 865,000 insurance claims that were made and analyzed,’ Hawley said. 

The Ethics & Public Policy Center published findings in April that evaluated 865,000 medical abortions prescribed between 2017–2023. It concluded that the rate of serious side effects was 22 times higher than indicated by the FDA label.  

‘That’s a sanitized way of saying they’re in very serious danger,’ Hawley said.

Critics of the study have said it lacks context and may overlook unrelated, complicating factors. 

Marjorie Dannenfelser, the president of Susan B. Anthony Pro-Life America, an anti-abortion advocacy group, shares Hawley’s concern about the pill’s safety. She also believes abortion pills are an easy way for women to access abortion — even in states that have passed restrictions on them.

‘This abortion pill is an instrument of beating back [state] sovereignty. State laws are being undermined. The abortion rate overall in this nation has gone up since Dobbs because of the abortion pill,’ Dannenfelser said, referring to the landmark 2022 case Dobbs v. Jackson that overturned a federal right to an abortion.

Susan B. Anthony Pro-Life America was one of the key groups calling on Republicans to cut Medicaid funding for abortions through Trump’s One, Big Beautiful Bill Act.

Anti-abortion advocates have zeroed in on access to mifepristone as a way to continue pushing back against abortion access — especially since the FDA approved remote prescriptions of the drug in the wake of COVID-19.

In June, the Supreme Court rejected a challenge brought by the Alliance for Hippocratic Medicine (AHM), arguing that the FDA had improperly approved mifepristone for use back in 2001, skirting safety requirements. 

Since then, mifepristone has remained widely available, but the Supreme Court’s ruling left the door open to future challenges to the FDA’s certification of the drug.

Like other critics of chemical abortions, Hawley has urged the FDA to undergo its own evaluation of whether abortion pills are safe, reliable products — a priority shared with HHS Secretary Robert F. Kennedy Jr.

‘We need to have a full and thorough review of the data related to mifepristone [and] the health risks related to mifepristone. We need to see the reinstatement of safety guardrails that have historically accompanied this drug,’ Hawley said.

The FDA did not immediately respond to Fox News Digital’s request for comment.

This post appeared first on FOX NEWS

Previous Post

Senate defies Trump on global tariffs as Republicans join Democrats in rare bipartisan vote

Next Post

Vance to meet with Duffy, aviation leaders as shutdown ‘gravely’ impacts crucial industry

Next Post
Vance to meet with Duffy, aviation leaders as shutdown ‘gravely’ impacts crucial industry

Vance to meet with Duffy, aviation leaders as shutdown ‘gravely’ impacts crucial industry

  • Trending
  • Comments
  • Latest
U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

February 19, 2025
KFC moves U.S. headquarters from Kentucky to Texas

KFC moves U.S. headquarters from Kentucky to Texas

February 19, 2025
How Companies Use Derivatives To Hedge Risk

How Companies Use Derivatives To Hedge Risk

February 19, 2025
How crazy popcorn buckets became big business for movie theaters

How crazy popcorn buckets became big business for movie theaters

February 19, 2025
An OpenAI IPO in 2026? Why it may not happen soon

An OpenAI IPO in 2026? Why it may not happen soon

0
From tariffs to DOGE, what companies are saying about the impact of MAGA policies

From tariffs to DOGE, what companies are saying about the impact of MAGA policies

0
Tesla’s law firm drafts Delaware bill that could salvage Musk pay package

Tesla’s law firm drafts Delaware bill that could salvage Musk pay package

0
Coca-Cola takes on Olipop and Poppi with new prebiotic soda brand, Simply Pop

Coca-Cola takes on Olipop and Poppi with new prebiotic soda brand, Simply Pop

0
An OpenAI IPO in 2026? Why it may not happen soon

An OpenAI IPO in 2026? Why it may not happen soon

November 30, 2025
Winners vs. losers in a bruised November: can the S&P 500 recover in December?

Winners vs. losers in a bruised November: can the S&P 500 recover in December?

November 30, 2025
Best retail stocks to own heading into the 2025 holiday season

Best retail stocks to own heading into the 2025 holiday season

November 30, 2025
Top S&P 500 Index, VOO, and SPY ETF news to watch this week

Top S&P 500 Index, VOO, and SPY ETF news to watch this week

November 30, 2025

    Get Smarter with Your Money – Sign Up for Free Financial Tips!


    Join our community of savvy savers and investors! By signing up, you'll receive weekly emails packed with personalized financial tips, budgeting hacks, and investment strategies tailored to your income level. Take control of your finances today – it’s free and only takes a minute!

    Recent News

    An OpenAI IPO in 2026? Why it may not happen soon

    An OpenAI IPO in 2026? Why it may not happen soon

    November 30, 2025
    Winners vs. losers in a bruised November: can the S&P 500 recover in December?

    Winners vs. losers in a bruised November: can the S&P 500 recover in December?

    November 30, 2025
    Best retail stocks to own heading into the 2025 holiday season

    Best retail stocks to own heading into the 2025 holiday season

    November 30, 2025
    Top S&P 500 Index, VOO, and SPY ETF news to watch this week

    Top S&P 500 Index, VOO, and SPY ETF news to watch this week

    November 30, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved

    No Result
    View All Result
    • About us
    • Contacts
    • Email Whitelisting
    • Investing and Stock News
    • Privacy Policy
    • Terms and Conditions
    • Thank you

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved